Related Experiment Videos
Choroidal hemangioma treated with photodynamic therapy using verteporfin
1Retina Associates of New Jersey, 628 Cedar Ln, Teaneck, NJ 07666, USA. smadreperla@hotmail.com
Archives of Ophthalmology (Chicago, Ill. : 1960)
|November 16, 2001
Summary
Photodynamic therapy with verteporfin effectively treats vision loss from circumscribed choroidal hemangioma by resolving subretinal fluid. This innovative treatment improved vision and reduced tumor size in all patients, with no noted complications.
Area of Science:
- Ophthalmology
- Medical Technology
Background:
- Subretinal fluid associated with circumscribed choroidal hemangioma causes vision loss.
- Effective treatment options for this condition are limited.
Observation:
- Three patients with subretinal fluid due to circumscribed choroidal hemangioma were treated with photodynamic therapy (PDT) using verteporfin.
- Standardized treatment parameters were applied: verteporfin at 6 mg/m(2) and laser light at 689 nm, 50 J/cm(2), 600 mW/cm(2) for 83 seconds.
- Pre- and post-treatment fluorescein angiography and ultrasonography were performed.
Findings:
- Complete resolution of subretinal fluid occurred within two weeks in all patients.
- Tumor leakage on fluorescein angiography was absent post-treatment.
- Reduced tumor thickness or complete flattening was observed in all treated eyes.
- Visual acuity improved in all patients.
- Average follow-up was 5.3 months with no complications.
Implications:
- Photodynamic therapy with verteporfin is a safe and effective treatment for circumscribed choroidal hemangioma.
- This therapy successfully eliminates subretinal fluid and enhances visual acuity.
- Further research into PDT for ocular tumors is warranted.